http://rdf.ncbi.nlm.nih.gov/pubchem/reference/5912453

Outgoing Links

Predicate Object
contentType Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't
endingPage 2201
issn 1473-4877
0300-7995
issueIdentifier 11
pageRange 2193-2201
publicationName Current Medical Research and Opinion
startingPage 2193
bibliographicCitation Nuijten MJC, Aultman R, Carpeño JDC, Vergnenègre A, Chouaid C, Walzer S, Siebert U. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Current Medical Research and Opinion. 2011 Oct 04;27(11):2193–201. doi: 10.1185/03007995.2011.626019.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c6c8ed79ee173ad09d191177ed922414
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_58efd57bc1a3e22943ad5eb81adfac93
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6f3a4782c583ad61779683ce6f3b279a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6425-7671
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-4290-5524
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79e9eb4bf02fa608a5ef180ffb7738fa
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63a67679ae1fb56958c9147fb3936829
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47bad2f2fe2953b8bef1a8f37cf78ea4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8eb286de061dd2a04b925ea4deb00f77
date 2011-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/21970659
https://doi.org/10.1185/03007995.2011.626019
isPartOf https://portal.issn.org/resource/ISSN/0300-7995
https://portal.issn.org/resource/ISSN/1473-4877
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3218
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer
discusses http://id.nlm.nih.gov/mesh/M0026156
http://id.nlm.nih.gov/mesh/M0009376
http://id.nlm.nih.gov/mesh/M0443627
http://id.nlm.nih.gov/mesh/M0227083
http://id.nlm.nih.gov/mesh/M0009679
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0024707
http://id.nlm.nih.gov/mesh/M0004505
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D000230Q000188
http://id.nlm.nih.gov/mesh/D002289Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D006147Q000031
http://id.nlm.nih.gov/mesh/D000068437
http://id.nlm.nih.gov/mesh/D000068258
http://id.nlm.nih.gov/mesh/D006147Q000008
http://id.nlm.nih.gov/mesh/D002945Q000627
http://id.nlm.nih.gov/mesh/D017239Q000008
http://id.nlm.nih.gov/mesh/D000230Q000473
http://id.nlm.nih.gov/mesh/D002945Q000008
http://id.nlm.nih.gov/mesh/D000230Q000401
http://id.nlm.nih.gov/mesh/D008390
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D018572
http://id.nlm.nih.gov/mesh/D005971Q000008
http://id.nlm.nih.gov/mesh/D005971Q000627
http://id.nlm.nih.gov/mesh/D006147Q000627
http://id.nlm.nih.gov/mesh/D016190Q000627
http://id.nlm.nih.gov/mesh/D017239Q000627
http://id.nlm.nih.gov/mesh/D061067Q000627
http://id.nlm.nih.gov/mesh/D016190Q000008
http://id.nlm.nih.gov/mesh/D061067Q000008
http://id.nlm.nih.gov/mesh/D002289Q000473
http://id.nlm.nih.gov/mesh/D002289Q000401
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID108157
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837

Total number of triples: 72.